Scott Platshon is recorded as CIO at Zymeworks Inc. (ZYME) since November 18, 2025 and Board Member at Zymeworks Inc. (ZYME) since February 17, 2025. Zymeworks Inc. reported in an 8-K filed November 18, 2025 that Scott Platshon was appointed Acting Chief Investment Officer, effective November 18, 2025. Zymeworks Inc. reported in an 8-K filed November 18, 2025 that Scott Platshon resigned as board of directors, effective November 16, 2025. Zymeworks Inc. reported in an 8-K filed February 18, 2025 that Scott Platshon was appointed Compensation Committee member, effective February 17, 2025. Equibles holds 4 filed executive changes naming Scott Platshon; each is listed under recent activity with its source filing. Scott Platshon has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Zymeworks Inc. on June 3, 2026. Zymeworks Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zymeworks Inc. includes Ali Tehrani (CEO), Kenneth Galbraith (CEO and CFO), Kristin Stafford (CFO) and 7 others.
“Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer.”
Zymeworks Inc. Form 8-K, filed November 18, 2025
· Read the filing
“On November 16, 2025, Mr. Scott Platshon submitted his resignation from the board of directors (the "Board") of Zymeworks Inc. (the "Company"), effective immediately.”
Zymeworks Inc. Form 8-K, filed November 18, 2025
· Read the filing
Scott Platshon on recent calls
“Since I'm about two months into this role as the chief business officer, I thought I'd just start with a quick introduction to myself and then give just a quick overview of the company.”
“Look, I think there's two questions embedded in that, which is sort of therapeutic areas for dealmaking and sort of the timing and cadence of deals. We think a lot about the world-class protein engineering team we have in Vancouver.”
